Biophytis to Participate in Four Key Events in Q4 2025

Press release

 Biophytis to Participate in Four Key Events in Q4 2025

Paris, France, Cambridge (Massachusetts, United States), September 30^th, 2025 – 7:00 a.m. CET – Biophytis SA ("the Company"), a pioneering company in the development of transformative therapies impacting longevity, today announces its participation in four major international events that reflect the complementarity of its development strategy: 

•       CF&B Midcap Events o Paris, September 30 – October 1, 2025 o Geneva, December 10, 2025

•       BIO-Europe (Vienna, November 3–5, 2025)

•       SCWD Annual Conference (Rome, December 11–13, 2025)

In Paris and Geneva, the Company will take part in the Midcap Events organized by CF&B, a leading platform for listed companies to engage with a wide range of institutional investors specializing in small and midcaps. Biophytis will present its recent progress, particularly in sarcopenia and obesity, and engage with the financial community on its development outlook.

In Vienna, Biophytis will participate in BIO-Europe 2025, the largest biotechnology partnering event in Europe, bringing together key stakeholders across the pharmaceutical and biopharmaceutical value chain. The Company will seize the opportunity to meet potential new industrial partners, explore possible collaborations, and lay the groundwork for strategic alliances to support its clinical development programs.

In Rome, Biophytis will attend the annual conference of the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD), a major international scientific event focused on muscle-wasting conditions related to aging and chronic diseases. This participation comes in the context of the upcoming launch of the Phase 3 SARA trial in sarcopenia, the most advanced clinical program in this indication worldwide. The Company will present its research and aims to strengthen its positioning within the medical and academic communities.

A Pivotal Fourth Quarter for Biophytis

With active participation in four major events, Biophytis reaffirms its ambition to be a central player in the development of transformative therapies impacting longevity. These events represent key opportunities to initiate new partnerships, enhance the visibility of its clinical programs, and secure the resources needed to support their advancement.

***

About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company’s ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com. 

Page 1 sur 2

Press release

Disclaimer

This press release contains forward-looking statements.  Forward-looking statements include all statements that are not historical facts.  In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forwardlooking statements are based on assumptions that Biophytis considers to be reasonable.  However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face" section from the Company’s 2023 Financial Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether because of new information or otherwise, except as required by law.

Biophytis Contacts 

Investor Relations

Investors@biophytis.com

US Investors

Pascal Nigen – Alpha Bronze

pnigen@alphabronzellc.com

Media contacts

Antoine Denry: antoine.denry@taddeo.fr – +33 6 18 07 83 27

Inès de Mandiargues: ines.demandiargues@taddeo.fr - +33 6 16 16 51 78

Page 2 sur 2